ClinicalTrials.gg
CompletedNCT03646331Updated Jan 11, 2019

Bioequivalence of Imeglimin Tablet Formulations

A Phase 1 interventional study of Imeglimin Reference product and Imeglimin in Bioequivalence, sponsored by Poxel SA. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-01-11.

Sponsored by Poxel SA · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is an open-label assessment of the bioequivalence of two 500 mg-tablet formulations of imeglimin (Tablet A [reference product] and Tablet B [test product]), in at least 16 healthy Caucasian volunteers.

02

Conditions studied

  • Bioequivalence
03

In context

Lead sponsor

Poxel SA is the lead sponsor of 14 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • : 18.5-29.9
  • Body weight ≥ 60 kg
  • willing to use reliable
  • able to give fully informed written consent.

Exclusion criteria

Exclusion Criteria:

  • Positive tests for \& C,
  • severe adverse reaction to any drug; sensitivity to trial medication and/or food allergies
  • drug or alcohol abuse
  • smoking of more than 5 cigarettes daily or drinking more than 5 cups of caffeinated drinks daily
  • over-the-counter medication, vitamins and herbal remedies, or prescribed medication in the 20 days before the first dose of trial medication (with the exception of paracetamol [acetaminophen] and oral );
  • participation in other clinical trials of unlicensed medicines, or loss of more than 400 mL blood, within the previous 3 months
  • vital signs outside the acceptable range
  • abnormal findings at the screening assessment; estimated (eGFR) at screening \< 80 mL/min/1.73 m2
  • acute or chronic illness
  • clinically relevant abnormal medical history or concurrent medical condition;
  • surgery or medical condition that might affect the absorption of medicines;
  • possibility that volunteer will not cooperate
  • pre-menopausal females who are pregnant or lactating, or who are sexually active and not using a reliable method of contraception;
  • objection by the volunteer's General Practitioner (GP).
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Tablet A in Session 1 and Tablet B in Session 2

    Tablet A = reference product Tablet B = test product

    Drug: Imeglimin Reference product · Drug: Imeglimin

  • Experimental
    Tablet B in Session 1 and Tablet A in Session 2

    Tablet A = reference product Tablet B = test product

    Drug: Imeglimin Reference product · Drug: Imeglimin

Interventions

  • DrugImeglimin Reference product

    Reference product

  • Test product (new formulation tablet)

06

What researchers measure

Primary outcomes

  1. Pk parameters of imeglimin

    Cmax: peak plasma concentration after dosing

    Time frame: from dosing up to 48h

Secondary outcomes

  1. PK parameters of Imeglimin

    AUC last: area Under the concentration time curve

    Time frame: from dosing up to 48h

  2. Incidence of treatment emergent adverse events (Safety and tolerability)

    Incidence of treatment emergent adverse events

    Time frame: From Day 1 to Day 15

07

Study locations

1 site
  • Hammersmith Medicines Research (HMR)
    London, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2018 to primary completion in Sep 2018, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2018
First posted
Aug 24, 2018
StartActual
Sep 3, 2018
Primary completionActual
Sep 27, 2018
CompletionActual
Oct 2, 2018
Last update
Jan 11, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 11, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03646331
Lead sponsor
Poxel SA
Responsible party
Sponsor
First posted
Aug 24, 2018
Start date
Sep 3, 2018
Primary completion
Sep 27, 2018
Completion
Oct 2, 2018
Last update
Jan 11, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Imeglimin

Start the discussion